Please describe your clinical practice. How many patients with Hypothalamic Obesity do you see on a yearly basis? What is the standard of care? What works best in your patients and why?

Can you please tell us about the details and mechanism of action for setmelanotide as it relates to weight loss? Could you give us the details on how treatment for hypothalamus damage involves replacing the lost hormones?

How often is Gastric bypass surgery considered an option by your patients?

Could you please comment on the: -17.2 percent mean percentage change in BMI (range: -37.2 percent, -6.7 percent);-15.8 percent mean change (range: -34.9 percent, -6.7 percent) in body weight from baseline weight of 107.1 kg (range, 39.0 kg, 141.4 kg) or 236.1 lb;-15.9 kg (range, -28.2 kg, -6.7 kg) or -35.1 lb mean weight loss from baseline.-19.5 mean percent change in BMI (range: -37.2 percent, -10 percent);-17.8 mean percent change (range: -34.9 percent, -10.7 percent) in body weight from baseline weight of 107.8 kg (range: 39.0 kg, 141.4 kg) or 236.1 lb;-17.8 kg (range: -28.2 kg, -9.5 kg) or -37.7 lb mean weight loss from baseline.How does this data compare to standard of care?

How likely would you be to prescribe IMCIVREE for Hypothalamic Obesity patients, if approved in the future?

How well do you suppose setmelanotide can work in other rare MC4R pathway diseases?